Search Results - "Richardson, Max W."

Supraphysiologic control over HIV-1 replication mediated by CD8 T cells expressing a re-engineered CD4-based chimeric antigen receptor by Leibman, Rachel S, Richardson, Max W, Ellebrecht, Christoph T, Maldini, Colby R, Glover, Joshua A, Secreto, Anthony J, Kulikovskaya, Irina, Lacey, Simon F, Akkina, Sarah R, Yi, Yanjie, Shaheen, Farida, Wang, Jianbin, Dufendach, Keith A, Holmes, Michael C, Collman, Ronald G, Payne, Aimee S, Riley, James L

“…HIV is adept at avoiding naturally generated T cell responses; therefore, there is a need to develop HIV-specific T cells with greater potency for use in HIV…”
Get full text

Potent and Broad Inhibition of HIV-1 by a Peptide from the gp41 Heptad Repeat-2 Domain Conjugated to the CXCR4 Amino Terminus by Leslie, George J, Wang, Jianbin, Richardson, Max W, Haggarty, Beth S, Hua, Kevin L, Duong, Jennifer, Secreto, Anthony J, Jordon, Andrea P O, Romano, Josephine, Kumar, Kritika E, DeClercq, Joshua J, Gregory, Philip D, June, Carl H, Root, Michael J, Riley, James L, Holmes, Michael C, Hoxie, James A

“…HIV-1 entry can be inhibited by soluble peptides from the gp41 heptad repeat-2 (HR2) domain that interfere with formation of the 6-helix bundle during fusion…”
Get full text

An NK-like CAR T cell transition in CAR T cell dysfunction by Good, Charly R., Aznar, M. Angela, Kuramitsu, Shunichiro, Samareh, Parisa, Agarwal, Sangya, Donahue, Greg, Ishiyama, Kenichi, Wellhausen, Nils, Rennels, Austin K., Ma, Yujie, Tian, Lifeng, Guedan, Sonia, Alexander, Katherine A., Zhang, Zhen, Rommel, Philipp C., Singh, Nathan, Glastad, Karl M., Richardson, Max W., Watanabe, Keisuke, Tanyi, Janos L., O’Hara, Mark H., Ruella, Marco, Lacey, Simon F., Moon, Edmund K., Schuster, Stephen J., Albelda, Steven M., Lanier, Lewis L., Young, Regina M., Berger, Shelley L., June, Carl H.

“…Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains ineffective in solid tumors, due in…”
Get full text

CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication by Tebas, Pablo, Jadlowsky, Julie K, Shaw, Pamela A, Tian, Lifeng, Esparza, Erin, Brennan, Andrea L, Kim, Sukyung, Naing, Soe Yu, Richardson, Max W, Vogel, Ashley N, Maldini, Colby R, Kong, Hong, Liu, Xiaojun, Lacey, Simon F, Bauer, Anya M, Mampe, Felicity, Richman, Lee P, Lee, Gary, Ando, Dale, Levine, Bruce L, Porter, David L, Zhao, Yangbing, Siegel, Don L, Bar, Katharine J, June, Carl H, Riley, James L

“…BackgroundWe conducted a phase I clinical trial that infused CCR5 gene-edited CD4+ T cells to determine how these T cells can better enable HIV cure…”
Get full text

Generation of human islet-specific regulatory T cells by TCR gene transfer by Hull, Caroline M, Nickolay, Lauren E, Estorninho, Megan, Richardson, Max W, Riley, James L, Peakman, Mark, Maher, John, Tree, Timothy I.M

“…Abstract Based on the success in animal models of type 1 diabetes (T1D), clinical trials of adoptive regulatory T cell (Treg) therapy are underway using…”
Get full text

CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication by Tebas, Pablo, Jadlowsky, Julie K, Shaw, Pamela A, Tian, Lifeng, Esparza, Erin, Brennan, Andrea L, Kim, Sukyung, Naing, Soe Yu, Richardson, Max W, Vogel, Ashley N, Maldini, Colby R, Kong, Hong, Liu, Xiaojun, Lacey, Simon F, Bauer, Anya M, Mampe, Felicity, Richman, Lee P, Lee, Gary, Ando, Dale, Levine, Bruce L, Porter, David L, Zhao, Yangbing, Siegel, Don L, Bar, Katharine J, June, Carl H, Riley, James L

Get full text

Stabilized Human TRIM5α Protects Human T Cells From HIV-1 Infection by Richardson, Max W, Guo, Lili, Xin, Frances, Yang, Xiaolu, Riley, James L

“…Rhesus (rh) but not human (hu) TRIM5α potently restricts human immunodeficiency virus (HIV)-1 infection. It is not clear why huTRIM5α fails to effectively…”
Get full text

Outcome of Simian-Human Immunodeficiency Virus Strain 89.6p Challenge following Vaccination of Rhesus Macaques with Human Immunodeficiency Virus Tat Protein by Silvera, Peter, Richardson, Max W, Greenhouse, Jack, Yalley-Ogunro, Jake, Shaw, Nigel, Mirchandani, Jyotika, Khalili, Kamel, Zagury, Jean-Francois, Lewis, Mark G, Rappaport, Jay

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

Lack of immunoediting in murine pancreatic cancer reversed with neoantigen by Evans, Rebecca A, Diamond, Mark S, Rech, Andrew J, Chao, Timothy, Richardson, Max W, Lin, Jeffrey H, Bajor, David L, Byrne, Katelyn T, Stanger, Ben Z, Riley, James L, Markosyan, Nune, Winograd, Rafael, Vonderheide, Robert H

“…In carcinogen-driven cancers, a high mutational burden results in neoepitopes that can be recognized immunologically. Such carcinogen-induced tumors may evade…”
Get full text

Kruppel-like factor 2 modulates CCR5 expression and susceptibility to HIV-1 infection by Richardson, Max W, Jadlowsky, Julie, Didigu, Chuka A, Doms, Robert W, Riley, James L

“…CCR5, a cell surface molecule critical for the transmission and spread of HIV-1, is dynamically regulated during T cell activation and differentiation. The…”
Get full text

Mode of Transmission Affects the Sensitivity of Human Immunodeficiency Virus Type 1 to Restriction by Rhesus TRIM5α by Richardson, Max W., Carroll, Richard G., Stremlau, Matthew, Korokhov, Nikolay, Humeau, Laurent M., Silvestri, Guido, Sodroski, Joseph, Riley, James L.

“…Article Usage Stats Services JVI Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley…”
Get full text

HIV Sequence Variation Associated With env Antisense Adoptive T-cell Therapy in the hNSG Mouse Model by Mukherjee, Rithun, Plesa, Gabriela, Sherrill-Mix, Scott, Richardson, Max W, Riley, James L, Bushman, Frederic D

“…The first use of lentiviral vectors in humans involved transduction of mature T-cells with an human immunodeficiency virus (HIV)–derived env antisense (envAS)…”
Get full text

Antibodies to Tat and Vpr in the GRIV cohort: differential association with maintenance of long-term non-progression status in HIV-1 infection by Richardson, Max W, Mirchandani, Jyotika, Duong, Joseph, Grimaldo, Sammy, Kocieda, Virginia, Hendel, Houria, Khalili, Kamel, Zagury, Jean-François, Rappaport, Jay

“…The HIV-1 regulatory protein Tat and the accessory protein Vpr are thought to stimulate viral replication and contribute to viral pathogenesis as extracellular…”
Get full text

T-cell receptor excision circles (TREC) and maintenance of long-term non-progression status in HIV-1 infection by RICHARDSON, Max W, SVERSTIUK, Andrij E, GRACELY, Edward J, HENDEL, Houria, KHALILI, Kamel, ZAGURY, Jean-Francois, RAPPAPORT, Jay

Get full text

Persistent Anti-Gag, -Nef, and -Rev IgM Levels as Markers of the Impaired Functions of CD4+ T-Helper Lymphocytes During SIVmac251 Infection of Cynomolgus Macaques by Régulier, Emmanuel G, Panemangalore, Reshma, Richardson, Max W, DeFranco, Jeremy J, Kocieda, Virginia, Gordon-Lyles, Devon C, Silvera, Peter, Khalili, Kamel, Zagury, Jean-François, Lewis, Mark G, Rappaport, Jay

“…This study analyzed the antigen-specific (Gag, Nef, Rev, and Tat) IgM, IgG, and IgA humoral responses during the first 200 days of SIVmac251 infection in…”
Get full text

Design, targeting, and initial screening of sTRSV-derived hairpin ribozymes for optimum helix 1 length and catalytic efficiency in vitro by Richardson, Max W, Hostalek, Linda, Dobson, Michelle, Hu, Jason, Shippy, Richard, Siwkowski, Andrew, Marmur, Jonathan D, Khalili, Kamel, Klotman, Paul E, Hampel, Arnold, Rappaport, Jay

“…Hairpin ribozymes derived from the negative strand of satellite RNAs from the tobacco ringspot virus (sTRSV) can be engineered to target and cleave a variety…”
Get more information

T-cell receptor excision circles (TREC) in SHIV 89.6p and SIVmac251 models of HIV-1 infection by Richardson, Max W, Sverstiuk, Andrij E, Silvera, Peter, Greenhouse, Jack, Lisziewicz, Julianna, Lori, Franco, Khalili, Kamel, Lewis, Mark G, Rappaport, Jay

“…T-cell receptor excision circles (TREC) may be a useful surrogate marker in HIV-1 infection for evaluating the likelihood of continued clinical stability…”
Get more information

Immunogenicity of HIV-1 IIIB and SHIV 89.6P Tat and Tat toxoids in rhesus macaques: induction of humoral and cellular immune responses by Richardson, Max W, Mirchandani, Jyotika, Silvera, Peter, Régulier, Emmanuel G, Capini, Christelle, Bojczuk, Paul M, Hu, Jason, Gracely, Edward J, Boyer, Jean D, Khalili, Kamel, Zagury, Jean-François, Lewis, Mark G, Rappaport, Jay

“…This study compared immune responses in rhesus macaques immunized with unmodified HIV-1 IIIB Tat, SHIV89.6P Tat, and carboxymethylated IIIB and 89.6P Tat…”
Get more information

Abstract 60: Induction of T cell dysfunction and NK-like T cell differentiation in vitro and in patients after CAR T cell treatment by Good, Charly R., Kuramitsu, Shunichiro, Samareh, Parisa, Donahue, Greg, Ishiyama, Kenichi, Ma, Yujie, Wellhausen, Nils, Tian, Lifeng, Agarwal, Sangya, Guedan, Sonia, Aznar, M. Angela, Alexander, Katherine A., Zhang, Zhen, Singh, Nathan, Richardson, Max W., Watanabe, Keisuke, Tanyi, Janos L., O'Hara, Mark H., Ruella, Marco, Lacey, Simon F., Moon, Edmund K., Schuster, Stephen J., Albelda, Steven M., Lanier, Lewis L., Young, Regina M., Berger, Shelley L., June, Carl H.

“…Abstract Chimeric antigen receptor (CAR) T cell therapy has achieved remarkable success in hematological malignancies but remains largely ineffective in solid…”
Get full text

CCR5-edited [CD4.sup.+] T cells augment HIV-specific immunity to enable post-rebound control of HIV replication by Tebas, Pablo, Jadlowsky, Julie K, Shaw, Pamela A, Tian, Lifeng, Esparza, Erin, Brennan, Andrea L, Kim, Sukyung, Naing, Soe Yu, Richardson, Max W, Vogel, Ashley N, Maldini, Colby R, Kong, Hong, Liu, Xiaojun, Lacey, Simon F, Bauer, Anya M, Mampe, Felicity, Richman, Lee P, Lee, Gary, Ando, Dale, Levine, Bruce L, Porter, David L, Zhao, Yangbing, Siegel, Don L, Bar, Katharine J, June, Carl H, Riley, James L

“…BACKGROUND. We conducted a phase I clinical trial that infused CCR5 gene-edited [CD4.sup.+] T cells to determine how these T cells can better enable HIV cure…”
Get full text